MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 20th - 21st June 2024 in Boston, USA. This event will have an introduction to turning biomarkers into companion diagnostics.\n\nEnquire Now @ https:\/\/events.marketsandmarkets.com\/2nd-annual-

4 views • 5 slides

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 20th - 21st June 2024 in Boston, USA. This event will have an introduction to turning biomarkers into companion diagnostics.\n\nBecome a Speaker @ \/\/events.marketsandmarkets.com\/2nd-annual-b

1 views • 6 slides

Dr. Jamie Herron, a Consultant Psychiatrist specializing in Huntington's Disease, presents research opportunities including sub-investigator roles in clinical trials like Wave SNP3 and biomarker studies. The portfolio outlines the genetic basis of Huntington's, associated symptoms, and the chance to

1 views • 6 slides

MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 20-21 June 2024 in Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA.\n\nRegister Now @ \/\/events.marketsandmarkets.com\/2nd-annual-biomarker-and-companion-diagnostics-conference-usa-edi

1 views • 6 slides

Introducing the 2nd Annual MarketsandMarkets ImmunoBio Series, a groundbreaking event uniting the realms of Biomarker and Immuno-Oncology, set to unfold on 14th - 15th October 2024 in Freiburg im Breisgau, Germany.\n\nRegister Now @ \/\/events.marketsandmarkets.com\/immunobio-series\/register

1 views • 6 slides

Introducing the 2nd Annual MarketsandMarkets ImmunoBio Series, a groundbreaking event uniting the realms of Biomarker and Immuno-Oncology, set to unfold on 14th - 15th October 2024 in Freiburg, Germany.\n\nRegister Now @ \/\/events.marketsandmarkets.

1 views • 5 slides

Dementia, a syndrome resulting from various diseases affecting nerve cells and brain function, leads to cognitive decline. Treatment approaches include pharmacological and non-pharmacological interventions such as biomarker monitoring, lifestyle modifications, and addressing risk factors like hypert

0 views • 12 slides

Colorado's comprehensive cancer programs are focusing on enhancing cancer surveillance by collecting biomarkers and prognostic factors statewide. The initiative involves multi-phase implementation, bidirectional reporting for genetic counseling services, and increasing testing for targeted therapies

0 views • 17 slides

Strong association of clinical biomarker - elevated DKK2 correlates with poor CRC prognosis. First-in-class therapeutic for colorectal cancer, targeting MSS CRC with multiple novel mechanisms of action and low risk for side effects. Complements current treatments like bevacizumab and shows efficacy

0 views • 11 slides

The Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) commenced in late 2006, with a cohort size and follow-up progress detailed. The study includes assessments and biomarker imaging, such as MRI, amyloid PET, and tau PET scans, with ongoing review cycles and data additions. Current

0 views • 12 slides